Further thoughts on preclinical animal models for cancer prevention: When is it best to start treatment? What are potential histopathologic endpoints?

Seminars in Oncology

Volumn 37, Issue 4, 2010, Pages 339-344

  Umar, Asad ^a   Della'Zanna, Gary ^a   Lubet, Ronald ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLCHOLANTHRENE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; AZO DYE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EXUSILINID; FENRETINIDE; FLAVONE DERIVATIVE; GEFITINIB; GLUCOCORTICOID; METHANOL; MOLECULAR MARKER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PIROXICAM; POLYCYCLIC AROMATIC HYDROCARBON; POLYPHENON E; RETINOID X RECEPTOR AGONIST; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SULINDAC SULFONE; UNCLASSIFIED DRUG;

BLADDER CANCER; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL CANCER; DRUG EFFICACY; DYSPLASIA; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HYPERPLASIA; LUNG ADENOCARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR MODEL; TUMOR PROMOTION; ANIMAL; BIOASSAY; DISEASE MODEL; NEOPLASMS; PATHOLOGY; TIME;

ANIMALS; DISEASE MODELS, ANIMAL; ENDPOINT DETERMINATION; HUMANS; NEOPLASMS; TIME FACTORS;

EID: 77956352743     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2010.07.001     Document Type: Article

References (31)

1. D.L. Wickerham, J.P. Costantino, and V.G. Vogel The use of tamoxifen and raloxifene for the prevention of breast cancer Recent Results Cancer Res. 181 2009 113 119
2. D. Albanes, O.P. Heinonen, and P.R. Taylor Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance J Natl Cancer Inst. 88 1996 1560 1570
3. I.M. Thompson, D. Pauler Ankerst, and C. Chi Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial J Clin Oncol. 25 2007 3076 3081
4. J.A. Miller Carcinogenesis by chemicals: an overviewG.H.A. Clowes memorial lecture Cancer Res. 30 1970 559 576
5. E.C. Miller, J.A. Miller, and R.R. Brown On the protective action of certain polycyclic aromatic hydrocarbons against carcinogenesis by aminoazo dyes and 2-acetylaminofluorene Cancer Res. 18 1958 469 477
6. C. Huggins, and J. Pataki Aromatic azo derivatives preventing mammary cancer and adrenal injury from 7,12-dimethylbenz(a)anthracene Proc Natl Acad Sci U S A 53 1965 791 796
7. L.W. Wattenberg Inhibition of carcinogenic and toxic effects of polycyclic hydrocarbons by phenolic antioxidants and ethoxyquin J Natl Cancer Inst. 48 1972 1425 1430
8. L.W. Wattenberg Chemoprevention of cancer Cancer Res. 45 1985 1 8
9. M.M. Bertagnolli, C.J. Eagle, and A.G. Zauber Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med. 355 2006 873 884
10. R.A. Gupta, and R.N. DuBois Combinations for cancer prevention Nat Med. 6 2000 974 975
11. C.J. Gurbbs, R.C. Moon, and M.B. Sporn Inhibition of mammary cancer by retinyl methyl ether Cancer Res. 37 1977 599 602
12. K. Watanabe, B.S. Reddy, and C.Q. Wong Effect of dietary undegraded carrageenan on colon carcinogenesis in F344 rats treated with azoxymethane or methylnitrosourea Cancer Res. 38 1978 4427 4430
13. L.R. Howe, K. Subbaramaiah, and J. Patel Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer Cancer Res. 62 2002 5405 5407
14. S. Raghow, M.Z. Hooshdaran, and S. Katiyar Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model Cancer Res. 62 2002 1370 1376
15. R.C. Moon, D.L. McCormick, and P.J. Becci Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse Carcinogenesis 3 1982 1469 1472
16. A.L. Sabichi, S.P. Lerner, and E.N. Atkinson Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer Clin Cancer Res. 14 2008 224 229
17. S.A. Stopera, L.C. Murphy, and R.P. Bird Evidence for a ras gene mutation in azoxymethane-induced colonic aberrant crypts in Sprague-Dawley rats: earliest recognizable precursor lesions of experimental colon cancer Carcinogenesis 13 1992 2081 2085
18. H. Li, P.M. Kramer, and R.A. Lubet Termination of piroxicam treatment and the occurrence of azoxymethane-induced colon cancer in rats Cancer Lett. 147 1999 187 193
19. B.S. Reddy, H. Maruyama, and G. Kelloff Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development Cancer Res. 47 1987 5340 5346
20. V.E. Steele, C.V. Rao, and Y. Zhang Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers Cancer Prev Res (Phila Pa) 2 2009 951 956
21. B.S. Reddy, T. Kawamori, and R.A. Lubet Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process Cancer Res. 59 1999 3387 3391
22. R.A. Lubet, V.E. Steele, and M.M. Juliana Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy J Urol. 183 2010 1598 1603
23. R.A. Lubet, C.S. Yang, and M.J. Lee Preventive effects of polyphenon E on urinary bladder and mammary cancers in rats and correlations with serum and urine levels of tea polyphenols Mol Cancer Ther. 6 2007 2022 2028
24. Y. Wang, Z. Zhang, and E. Kastens Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice Cancer Res. 63 2003 4389 4395
25. Z. Zhang, Q. Liu, and L.E. Lantry A germ-line p53 mutation accelerates pulmonary tumorigenesis: p53-independent efficacy of chemopreventive agents green tea or dexamethasone/myo-inositol and chemotherapeutic agents Taxol or Adriamycin Cancer Res. 60 2000 901 907
26. Y. Yan, Y. Lu, and M. Wang Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer Mol Cancer Res. 4 2006 971 981
27. M.N. Gould, R.A. Lubet, and G.J. Kelloff Inherited susceptibility and acquired allelic imbalance in rat mammary carcinogenesis J Cell Biochem Suppl. 25 1996 37 40
28. R.F. Logan, M.J. Grainge, and V.C. Shepherd Aspirin and folic acid for the prevention of recurrent colorectal adenomas Gastroenterology 134 2008 29 38
29. N.L. Cho, M. Redston, and A.G. Zauber Aberrant crypt foci in the adenoma prevention with celecoxib trial Cancer Prev Res (Phila Pa) 1 2008 21 31
30. M.G. Mutch, R.E. Schoen, and J.W. Fleshman A multicenter study of prevalence and risk factors for aberrant crypt foci Clin Gastroenterol Hepatol. 7 2009 568 574
31. F.L. Meyskens Jr, C.E. McLaren, and D. Pelot Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial Cancer Prev Res (Phila Pa) 1 2008 32 38